Literature DB >> 19881357

On the use of adjusted cross-sectional estimators of HIV incidence.

Rui Wang1, Stephen W Lagakos.   

Abstract

OBJECTIVE: To elucidate when and how cross-sectional estimators of HIV incidence rates based on a sensitive and less sensitive diagnostic test should be adjusted.
METHODS: Evaluate the statistical properties of unadjusted and adjusted cross-sectional estimators of HIV incidence, including the adjusted estimators considered by McDougal et al, for the 2 settings where (a) all infected subjects eventually become reactive to the less sensitive test, and (b) a subset of infected subjects indefinitely remain nonreactive to the less sensitive test. Derive the maximum likelihood estimator of incidence for the latter setting and use analytical results and simulation studies to compare the performance of the various estimators.
RESULTS: When every infected subject would eventually become reactive to the less sensitive test, the McDougal adjusted estimator is uniformly less precise than the unadjusted estimator and more susceptible to bias. When a subset of the infected population would indefinitely remain nonreactive to the less sensitive test, the McDougal adjusted estimator is less precise than the maximum likelihood estimator, which coincides with an estimator developed by McWalter and Welte using a mathematical modeling approach. When the assumed model is incorrect, the unadjusted estimator overestimates incidence, whereas the maximum likelihood estimator can be biased in either direction.
CONCLUSIONS: The standard unadjusted cross-sectional estimator of HIV incidence should be used when all infected individuals would eventually become reactive to the less sensitive test. When a subset of individuals would indefinitely remain nonreactive to the less sensitive test, the maximum likelihood estimator for this setting should be used. Characterizing the proportion of individuals who would indefinitely remain nonreactive is crucial for accurate estimation of HIV incidence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19881357      PMCID: PMC3682673          DOI: 10.1097/QAI.0b013e3181c080a7

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  14 in total

1.  Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay.

Authors:  John W Hargrove; Jean H Humphrey; Kuda Mutasa; Bharat S Parekh; J Steve McDougal; Robert Ntozini; Henry Chidawanyika; Lawrence H Moulton; Brian Ward; Kusum Nathoo; Peter J Iliff; Ekkehard Kopp
Journal:  AIDS       Date:  2008-02-19       Impact factor: 4.177

2.  A Simplified Formula for Inferring HIV Incidence from Cross-Sectional Surveys Using a Test for Recent Infection.

Authors:  Alex Welte; Thomas A McWalter; Till Bärnighausen
Journal:  AIDS Res Hum Retroviruses       Date:  2009-01       Impact factor: 2.205

3.  Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional analysis using the BED capture enzyme immunoassay.

Authors:  J Steven McDougal; Bharat S Parekh; Michael L Peterson; Bernard M Branson; Trudy Dobbs; Marta Ackers; Marc Gurwith
Journal:  AIDS Res Hum Retroviruses       Date:  2006-10       Impact factor: 2.205

4.  Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence.

Authors:  Bharat S Parekh; M Susan Kennedy; Trudy Dobbs; Chou-Pong Pau; Robert Byers; Timothy Green; Dale J Hu; Suphak Vanichseni; Nancy L Young; Kachit Choopanya; Timothy D Mastro; J Steven McDougal
Journal:  AIDS Res Hum Retroviruses       Date:  2002-03-01       Impact factor: 2.205

5.  Estimating HIV incidence based on combined prevalence testing.

Authors:  Raji Balasubramanian; Stephen W Lagakos
Journal:  Biometrics       Date:  2009-04-13       Impact factor: 2.571

6.  Improved classification of recent HIV-1 infection by employing a two-stage sensitive/less-sensitive test strategy.

Authors:  Niel T Constantine; Anne M Sill; Noreen Jack; Kristen Kreisel; Jeffrey Edwards; Thomas Cafarella; Harry Smith; Courtenay Bartholomew; Farley R Cleghorn; William A Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2003-01-01       Impact factor: 3.731

7.  Estimation of current human immunodeficiency virus incidence rates from a cross-sectional survey using early diagnostic tests.

Authors:  R Brookmeyer; T C Quinn
Journal:  Am J Epidemiol       Date:  1995-01-15       Impact factor: 4.897

8.  New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.

Authors:  R S Janssen; G A Satten; S L Stramer; B D Rawal; T R O'Brien; B J Weiblen; F M Hecht; N Jack; F R Cleghorn; J O Kahn; M A Chesney; M P Busch
Journal:  JAMA       Date:  1998-07-01       Impact factor: 56.272

9.  Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa.

Authors:  Etienne Karita; Matt Price; Eric Hunter; Elwyn Chomba; Susan Allen; Lin Fei; Anatoli Kamali; Eduard J Sanders; Omu Anzala; Michael Katende; Nzeera Ketter
Journal:  AIDS       Date:  2007-02-19       Impact factor: 4.177

10.  HIV incidence in rural South Africa: comparison of estimates from longitudinal surveillance and cross-sectional cBED assay testing.

Authors:  Till Bärnighausen; Claudia Wallrauch; Alex Welte; Thomas A McWalter; Nhlanhla Mbizana; Johannes Viljoen; Natalie Graham; Frank Tanser; Adrian Puren; Marie-Louise Newell
Journal:  PLoS One       Date:  2008-11-04       Impact factor: 3.240

View more
  13 in total

1.  A new general biomarker-based incidence estimator.

Authors:  Reshma Kassanjee; Thomas A McWalter; Till Bärnighausen; Alex Welte
Journal:  Epidemiology       Date:  2012-09       Impact factor: 4.822

2.  Augmented cross-sectional studies with abbreviated follow-up for estimating HIV incidence.

Authors:  B Claggett; S W Lagakos; R Wang
Journal:  Biometrics       Date:  2011-06-13       Impact factor: 2.571

3.  Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection.

Authors:  Rui Wang; Jia Weng; Sikhulile Moyo; Debanjan Pain; Christopher D Barr; Dorcas Maruapula; Dineo Mongwato; Joseph Makhema; Vladimir Novitsky; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-19       Impact factor: 2.205

4.  HIV incidence determination in the United States: a multiassay approach.

Authors:  Oliver Laeyendecker; Ron Brookmeyer; Matthew M Cousins; Caroline E Mullis; Jacob Konikoff; Deborah Donnell; Connie Celum; Susan P Buchbinder; George R Seage; Gregory D Kirk; Shruti H Mehta; Jacquie Astemborski; Lisa P Jacobson; Joseph B Margolick; Joelle Brown; Thomas C Quinn; Susan H Eshleman
Journal:  J Infect Dis       Date:  2012-11-05       Impact factor: 5.226

5.  Evaluation of the false recent classification rates of multiassay algorithms in estimating HIV type 1 subtype C incidence.

Authors:  Sikhulile Moyo; Tessa LeCuyer; Rui Wang; Simani Gaseitsiwe; Jia Weng; Rosemary Musonda; Hermann Bussmann; Madisa Mine; Susan Engelbrecht; Joseph Makhema; Richard Marlink; Marianna K Baum; Vladimir Novitsky; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2013-09-06       Impact factor: 2.205

6.  A likelihood estimation of HIV incidence incorporating information on past prevalence.

Authors:  Lesego Gabaitiri; Henry G Mwambi; Stephen W Lagakos; Marcello Pagano
Journal:  S Afr Stat J       Date:  2013-03

7.  Estimation of HIV incidence using multiple biomarkers.

Authors:  Ron Brookmeyer; Jacob Konikoff; Oliver Laeyendecker; Susan H Eshleman
Journal:  Am J Epidemiol       Date:  2013-01-09       Impact factor: 4.897

8.  Mixture models for calibrating the BED for HIV incidence testing.

Authors:  Severin Guy Mahiane; Agnès Fiamma; Bertran Auvert
Journal:  Stat Med       Date:  2014-05-10       Impact factor: 2.373

Review 9.  Moving towards a reliable HIV incidence test - current status, resources available, future directions and challenges ahead.

Authors:  G Murphy; C D Pilcher; S M Keating; R Kassanjee; S N Facente; A Welte; E Grebe; K Marson; M P Busch; P Dailey; N Parkin; J Osborn; S Ongarello; K Marsh; J M Garcia-Calleja
Journal:  Epidemiol Infect       Date:  2016-12-22       Impact factor: 4.434

10.  A comparison of biomarker based incidence estimators.

Authors:  Thomas A McWalter; Alex Welte
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.